Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMC128 with Nivolumab in NSCLC, Melanoma, or RCC
NCT05354102Phase 1Active, not recruiting
- Sponsor
- Biomica
- Start
- May 2022
- Primary completion
- May 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BMC128 in non-small cell lung cancer (NSCLC), melanoma and renal cell carcinoma (RCC), sponsored by Biomica. Primary endpoint: Treatment Emergent Adverse Events at 1 year. Started May 2022; status: active, not recruiting.
02
Drugs
BMC128
03
Conditions
non-small cell lung cancer (NSCLC)melanomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05354102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05354102.